US 12410232
Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
granted A61KA61K2039/552A61K40/11
Quick answer
US patent 12410232 (Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor) held by The Board of Regents of the University of Texas System expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/552, A61K40/11, A61K40/31, A61K40/4221